A 48-week real-world outcome of tralokinumab treatment for atopic dermatitis: Systemic therapy-naïve versus -experienced patients

Supplementary Figure 1. The transition of eczema area and severity index (EASI) on four anatomical sites in patients with atopic dermatitis treated with tralokinumab. EASI scores on head and neck, trunk, upper limbs, or lower limbs are shown as means of systemic therapy–naïve patients (n = 92, green) or systemic therapy–experienced patients (n = 84, purple) during the 48-week treatment. All indices from week 4 through week 48 were significantly lower than baseline values in each group (p < 0.01 by repeated-measures ANOVA with Bonferroni correction). *p < 0.05, **p < 0.01, versus value of systemic therapy–experienced patients at each time-point, by Student’s t-test.

Supplementary Figure 2. Achievement rates of eczema area and severity index (EASI) 50, EASI 75, EASI 90, EASI 100, and investigator’s global assessment (IGA) 0/1 in patients with atopic dermatitis treated with tralokinumab. Data are shown as percentages for systemic therapy–naïve patients (n = 92, green) or systemic therapy–experienced patients (n = 84, purple) during the 48-week treatment. *p < 0.05, **p < 0.01, versus value of systemic therapy–experienced patients at each time-point, by Fisher’s exact test.

Supplementary Figure 3. Achievement rates of peak pruritus numerical rating scale (PP-NRS) 4 and atopic dermatitis control tool (ADCT) 7 in patients with atopic dermatitis treated with tralokinumab. Data are shown as percentages for systemic therapy–naïve patients (n = 92, green) or systemic therapy–experienced patients (n = 84, purple) during the 48-week treatment. *p < 0.05, **p < 0.01, versus value of systemic therapy–experienced patients at each time-point, by Fisher’s exact test.

Supplementary Figure 4. The transition of laboratory indexes in patients with atopic dermatitis treated with tralokinumab. Serum IgE, thymus and activation-regulated chemokine (TARC), lactate dehydrogenase (LDH), and total eosinophil count (TEC) are shown as medians for systemic therapy–naïve patients (n = 92, green) or systemic therapy–experienced patients (n = 84, purple) during the 48-week treatment.
*p < 0.05, ** p < 0.01, versus value of systemic therapy–experienced patients at each time-point, by Mann–Whitney U test.
Friedman's test with Bonferroni’ s correction detected significant differences from baseline values at following time-periods in each group:
1. IgE: weeks 12–48 (p < 0.01) in systemic therapy–naïve group and week 4 (p < 0.05) and weeks 12–48 (p < 0.01) in systemic therapy–experienced group.
2. TARC: weeks 4–48 (p < 0.01) in both groups.
3. LDH: week 24 (p < 0.05) and weeks 36 and 48 (p < 0.01) in systemic therapy-naïve group and weeks 4, 12 and 24 (p < 0.01), week 36 (p < 0.05) and week 48 (p < 0.01) in systemic therapy–experienced group.
4. TEC: no significant differences in either group